At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Enzalutamidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study Of Continuous Oral Dosing Of A Novel Antiandrogen Mdv3100, In Castration-resistant Bone Metastatic Prostate Cancer Patients Evaluating The Tumor Micro-enviroment
In Brief
A Phase 2 clinical trial evaluating Enzalutamide for Metastatic Progressive Castration-resistant Prostate Cancer. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionFeb 2012
Study CompletionAug 2013
TodayJul 2026
First PostedMar 23, 2010
Enrollment StartFeb 18, 2010
Primary CompletionFeb 29, 2012
Study CompletionAug 31, 2013
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 16.3 years ago
Interventions
Enzalutamidedrug